US 11,732,034 B2
Tau-binding antibodies
David Edward Ormonde Knight, Slough (GB); Terence Seward Baker, Slough (GB); David James McMillan, Slough (GB); Robert Anthony Griffin, Slough (GB); Georges Mairet-Coello, Brussels (BE); Patrick Downey, Brussels (BE); and Jean-Philippe Courade, Brussels (BE)
Assigned to UCB BIOPHARMA SRL, Brussels (BE)
Filed by UCB BIOPHARMA SRL, Brussels (BE)
Filed on Dec. 29, 2020, as Appl. No. 17/136,189.
Application 17/136,189 is a continuation of application No. 16/409,945, filed on May 13, 2019, granted, now 10,889,640.
Application 16/409,945 is a continuation of application No. 15/742,087, granted, now 10,287,343, previously published as PCT/EP2016/065813, filed on Jul. 5, 2016.
Claims priority of application No. 15175522 (EP), filed on Jul. 6, 2015.
Prior Publication US 2021/0115121 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 14/47 (2006.01); A61P 25/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); C07K 14/4711 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 15 Claims
 
1. An isolated monoclonal Tau-binding antibody or binding fragment thereof, conjugated to one or more effector molecule or a detectable label, wherein said Tau-binding antibody or binding fragment thereof comprises:
a light chain variable region comprising SEQ ID NO: 1 (CDR1), SEQ ID NO: 2 (CDR2), and SEQ ID NO: 3 (CDR3); and
a heavy chain variable region comprising SEQ ID NO: 4 (CDR1), SEQ ID NO: 5 (CDR2), and SEQ ID NO:6 (CDR3).